A Phase 1 study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor in patients with refractory solid tumor malignancies and lymphomas

PURPOSE: To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic-pharmacodynamic profile of the heat shock protein 90 (Hsp90) inhibitor PF-04929113 (SNX-5422) in patients with advanced solid tumors and lymphomas. METHODS: This was a single institution, phase I, dose-escalation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rajan, Arun, Kelly, Ronan J., Trepel, Jane B., Kim, Yeong Sang, Alarcon, Sylvia V., Kummar, Shivaani, Gutierrez, Martin, Crandon, Sonja, Zein, Wadih M., Jain, Lokesh, Mannargudi, Baskar, Figg, William D., Houk, Brett E., Shnaidman, Michael, Brega, Nicoletta, Giaccone, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3207004/
https://ncbi.nlm.nih.gov/pubmed/21908572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-0821
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados